维普期刊资源整合服务平台（V6.5）

106篇 您的检索式：作者名="MASSUTI B"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	ERCC1 mRNA-based ran- domized phase Ⅲ trial of docetaxel doublets with cisplatin or gemcitabine in stage Ⅳ non-small-cell lung cancer patients显示文摘	Rosell R Cobo M Massuti B	2005	J Clin Oncol2005，23，16：	1
2	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer:a Spanish lung cancer group trial显示文摘	Camps C Massuti B Jiménez A	2006	Ann Oncol2006，17，：	1
3	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TID study 显示文摘	Diaz- Rubio E G6mez- Espa a A Massuti B	2012	Oncologist2012，17，1：	1
4	Two secondline docetaxel dose-schedules in advanced non-small cell lung cancer (NSCLC):a spanishl lung cancer group (SLCG) phase Ⅲ trial 显示文摘	Camps C Massuti B Jimenez AM	2003	Lung Cancer2003，41，：	1
5	Three-week schedule of irinotecan and cisplatin in advanced non-smallcell lung cancer: a multicenter phase Ⅱ study显示文摘	Domine M Massuti B	2003	Lung Cancer2003，39，2：	1
6	Customizing cisplatin based on quantitative excision repair cross-complementing Ⅰ mRNA expres- sion:aphase Ⅲ trial in non-small-cell lung cancer显示文摘	Cobo M Isla D Massuti B	2007	J Clin On- col2007，25，19：	1
7	Selectivity of diamond- and squaremesh codends in the deepwater crustacean trawl fishery off the Balearic Islands (western Mediterranean) 显示文摘	Guijarro B Massuti E	2006	ICES J Mar Sci2006，63，1：	1
8	Customizing cisplatin based on quantitative excision repair cross-complementing1 mRNA expression:a phase Ⅲ trial in non-small-cell lung cancer显示文摘	Cobo M Isla D Massuti B	2007	J Clin Oncol2007，25，19：	1
9	Two secondline docetaxel dose schedules in advanced non-small cell lung cancer (NSCLC):A Spanish Lung Cancer Group (SLCG) phase Ⅲ trial显示文摘	Camps C Massuti B Jimenez AM	2003	Lung Cancer2003，41，：	1
10	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study显示文摘	Cardenal F Domine M Massuti B	2003	Lung Cancer2003，39，2：	1
11	Customizing cisplatin based on quantitativeexcisionrepaircross-complementing 1 mRNA expression:a phase Ⅲ trial in non-small-cell lung cancer显示文摘	Cobo M Isla D Massuti B	2007	J Clin Onco12007，25，19：	1
12	Randomized phase Ⅲ study of 3-weekly versus weekly docetaxel in pretreat- ed advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial显示文摘	Camps C Massuti B Jimenez A	2006	Ann Oncol2006，17，3：	1
13	Multicenter prospective trial of customized Erlotinib for advanced non-small cell lung cance (rN- SCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial 显示文摘	Massuti B Moran T Porta R	2009	J Clin Oncol (Meeting Abstracts)2009，27，15：	1
14	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single?agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study显示文摘	Diaz-Rubio E Gomez-Espana A Massuti B	2012	Oncologist2012，17，1：	1
15	Two second -line docetaxel dose-schedules in advanced non-small cell lung cancer (NSCLC):a Spanish Lung Cancer Group (SLCG) phase Ⅲ trial显示文摘	Camps C Massuti B Jimenez AM	2003	Lung Cancer2003，41，：	1
16	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression : a phase Ⅲ trial in non-small-cell lung cancer 显示文摘	Cobo M Isla D Massuti B	2007	J Clin Oncol2007，25，19：	1
17	Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer(NSCLC) patients with epidermal growth factor receptor(EGFR)mutations:Final results of the Spanish Lung Cancer Group(SLCG)trial显示文摘	Massuti B Morán T Porta R	2009	J Clin Oncol2009，27，15：	1
18	Customizing Cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase m thai in non-small-cell lung cancer显示文摘	Cobo M Isla D Massuti B	2007	J Clin Oncol2007，25，19：	1
19	First -line XE- LOX plus bevacizumab folkwed by XELOX plus bevacizumab or single - agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study 显示文摘	Diaz -Rubio E Gomez -Espana A Massuti B	2012	Oncologist2012，17，1：	1
20	Randomized phase Ⅲ study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Group Trial 显示文摘	Camps C Massuti B Jimenez A	2006	Annals of Oncology2006，17，3：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示